Merz Pharmaceuticals GmbH
https://www.merz.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Merz Pharmaceuticals GmbH
US Forming Industry Consortia To Prepare For Future Pandemics And Global Supply Chain Disruptions
HHS agencies look to build on COVID-19 experience by developing quicker public/private responses to pandemics and supply chain threats.
BARDA Lays Out Vision For Next Pandemic: Vaccines For The US Within 130 Days
Federal agency seeks dialogue with industry on how to enable surge capacity for pandemic vaccines without cutting back on other production.One key factor: workforce development.
As Emergent Partnership Dissolves, BARDA Looks To Revamp Post-COVID Pandemic Preparedness
BARDA terminates CIADM contract in wake of vaccine cross-contamination incident, begins discussion with industry about next steps for rapid pandemic response capabilities.
With Vuity Approval, AbbVie Continues Stepping Into Eye Care
AbbVie had no presence in ophthalmic medicine other than a single indication for Humira before the Allergan merger, but now has a growing eye care portfolio, including early FDA approval of Vuity for presbyopia.
Company Information
- Industry
- Diversified
- Other Names / Subsidiaries
-
- BioteCon Therapeutics GmbH
- Cabochon Aesthetics, Inc.
- ON Light Sciences, Inc.
- Ulthera, Inc.
- Merz Pharmaceuticals GmbH
- Merz Pharma France
- Merz North America, Inc.
- Merz Pharma (Schweiz) Ag
- Merz Pharma GmbH